Schubart A, Anderson K, Mainolfi N, et al. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc Natl Acad Sci U S A. 2019;116(16):7926–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cancado RD, Araujo ADS, Sandes AF, et al. Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. Hematol Transfus Cell Ther. 2021;43(3):341–8.

Article  PubMed  Google Scholar 

Dingli D, Matos JE, Lehrhaupt K, et al. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey. Ann Hematol. 2022;101(2):251–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang H, Rizk DV, Perkovic V, et al. Results of a randomized double-blind placebo-controlled phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. Kidney Int. 2023;105(1):189–99.

Article  PubMed  Google Scholar 

Novartis Pharmaceuicals. FABHALTA® (iptacopan) capsules, for oral use: US prescribing information. 2023. https://www.fda.gov. Accessed 18 Jan 2024.

Novartis Pharmaceuicals. Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH [media release]. 6 Dec 2023. https://www.novartis.com.

Novartis Pharmaceuticals. Q2 2023 results: investor presentation. 2022. https://www.novartis.com/. Accessed 18 Jan 2024.

Novartis Pharmaceuticals. Novartis pipeline as of December 31, 2022. 2022. https://www.novartis.com. Accessed 18 Jan 2024.

Schmouder R, Junge G, Nidamarthy PK, et al. A first-in-human, phase 1 study to assess the pharmacodynamic properties of single-dose iptacopan (CLNP023X2101) [abstract]. Blood. 2023;142(Suppl 1):4096.

Article  Google Scholar 

Jang JH, Wong L, Ko BS, et al. Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study. Blood Adv. 2022;6(15):4450–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Risitano AM, Röth A, Soret J, et al. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. Lancet Haematol. 2021;8(5):e344–54.

Article  CAS  PubMed  Google Scholar 

Risitano AM, Roth A, Kulasekararaj A, et al. Oral iptacopan monotherapy increases paroxysmal nocturnal hemoglobinuria (PNH) red blood cell clone size via control of intra- and extravascular hemolysis in anti-C5-treated PNH patients with anemia [abstract no. MDS-273]. Clin Lymphoma Myeloma Leuk. 2023;23(Suppl 1):S360.

Article  Google Scholar 

Risitano AM, Röth A, Kulasekararaj A, et al. Oral iptacopan monotherapy increases paroxysmal nocturnal hemoglobinuria (PNH) red blood cell clone size via control of intra- and extravascular hemolysis in anti-C5-treated PNH patients with anemia [abstract no. S182]. HemaSphere. 2023;7(Suppl 3):189–90.

Google Scholar 

Zhang M, Wang X, Yang C, et al. The change of complement deposition after complement inhibitor treatment in paroxysmal nocturnal hemoglobinuria patients [abstract]. Blood. 2023;142(Suppl 1):1350–1.

Article  Google Scholar 

Risitano A, de Latour RP, Yap ES, et al. Dose-exposure-response relationships of biomarkers and efficacy measures with iptacopan, a complement factor b inhibitor, in patients (pts) with paroxysmal nocturnal hemoglobinuria (PNH) with or without concomitant anti-C5 therapy [abstract]. Blood. 2022;140(Suppl 1):5803–4.

Article  Google Scholar 

Baltcheva I, Bartels C, Valentin M-A, et al. Exposure-response relationships between the factor B inhibitor iptacopan and complement biomarkers in healthy volunteers and patients (pts) with paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy (C3g) or IgA nephropathy (IgAN) [abstract]. Blood. 2023;142(Suppl 1):5640–1.

Article  Google Scholar 

Risitano AM, Peffault de Latour R, Jang JH, et al. exposure-response relationships between the complement factor B inhibitor iptacopan and lactate dehydrogenase (LDH) and hemoglobin (Hb) in patients (pts) with paroxysmal nocturnal hemoglobinuria (PNH) [abstract]. Blood. 2023;142(Suppl 1):5643.

Article  Google Scholar 

Schmouder R, Kaetterer N, Kulmatycki K, et al. A phase 1 study to assess the effect of supratherapeutic doses of iptacopan on cardiac conduction parameters and safety [abstract]. Blood. 2023;142(Suppl 1):5644.

Article  Google Scholar 

DeLise A, Zamurovic N, Hansen R, et al. Results of preclinical animal studies to evaluate the effect of iptacopan on pregnancy-related outcomes [abstract]. Blood. 2023;142(Suppl 1):4094–5.

Article  Google Scholar 

James AD, Kulmatycki K, Poller B, et al. Absorption, distribution, metabolism, and excretion of [14C]iptacopan in healthy male volunteers and in in vivo and in vitro studies. Drug Metab Dispos. 2023;51(7):873–83.

Article  CAS  PubMed  Google Scholar 

Wong E, Nester C, Cavero T, et al. Efficacy and safety of iptacopan in patients with C3 glomerulopathy. Kidney Int Rep. 2023;8(12):2754–64.

Article  PubMed  PubMed Central  Google Scholar 

Schmouder R, Junge G, Nidamarthy P, et al. Japanese and Whites share similar iptacopan pharmacokinetics and pharmacodynamics [abstract no. 4463]. Nephrol Dial Transplant. 2023;38(Suppl 1):i400–1.

Google Scholar 

de Latour RP, Roeth A, Kulasekararaj A, et al. Oral monotherapy with iptacopan, a proximal complement inhibitor of Factor B, has superior efficacy to intravenous terminal complement inhibition with standard of care eculizumab or ravulizumab and favorable safety in patients with paroxysmal nocturnal hemoglobinuria and residual anemia: results from the randomized, active-comparator-controlled, open-label, multicenter, phase III APPLY-PNH study [abstract]. Blood. 2022;140:5–9.

Google Scholar 

Risitano AM, Han B, Kulasekararaj A, et al. Categorization of hematological responses to oral iptacopan monotherapy in anti-C5-treated patients with paroxysmal nocturnal hemoglobinuria (PNH) and persistent anemia in the phase III APPLY-PNH trial and complement inhibitor-naïve patients in the phase III APPOINT-PNH trial [abstract]. Blood. 2023;142(Suppl 1):4084–6.

Article  Google Scholar 

Risitano AM, de Castro CM, Han B, et al. Patient-reported improvements in fatigue and health-related quality of life in the phase 3 studies APPLY-PNH and APPOINT-PNH evaluating the use of iptacopan in C5 inhibitor-treated and treatment-naïve patients with paroxysmal nocturnal hemoglobinuria [abstract]. Blood. 2023;142(Suppl 1):487.

Article  Google Scholar 

Risitano AM, Kulasekararaj A, Roeth A, et al. Factor B inhibition with oral iptacopan monotherapy demonstrates sustained long-term efficacy and safety in anti-C5-treated patients (pts) with paroxysmal nocturnal hemoglobinuria (PNH) and persistent anemia: final 48-week results from the multicenter, phase III APPLY-PNH trial [abstract]. Blood. 2023;142(Suppl 1):571–5.

Article  Google Scholar 

Röth A, Peffault de Latour R, Soret J, et al. Use of the oral complement factor B inhibitor iptacopan in patients (pts) with paroxysmal nocturnal hemoglobinuria (PNH) with persistent hemolysis despite anti-C5 therapy: long-term efficacy and safety after stopping eculizumab (ECU) [abstract no. V576]. Oncol Res Treat. 2022;45(Suppl 2):173–4.

Google Scholar 

Risitano A, Han B, Ueda Y, et al. Oral complement factor B inhibitor iptacopan monotherapy improves hemoglobin to normal/near-normal levels in paroxysmal nocturnal hemoglobinuria patients naïve to complement inhibitors: phase III APPOINT-PNH trial [abstract no. OS12-06]. In: 49th Annual Meeting of the European Society for Blood and Marrow Transplantation. 2023.

Jang J-H, Wong LLL, Ko B-S, et al. 12-month analysis of a phase 2 study of iptacopan (LNP023) monotherapy for paroxysmal nocturnal hemoglobinuria [abstract]. Blood. 2021;138(Suppl 1):2173–4.

Article  Google Scholar 

De Castro C, Scheinberg P, Han B, et al. Patient experience interviews with a novel treatment iptacopan for paroxysmal nocturnal hemoglobinuria [abstract]. Blood. 2023;142(Suppl 1):7339–41.

Article  Google Scholar 

Meier M. An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy: interim analysis of a phase 2 study [abstract no OC 61]. Swiss Med Wkly. 2022;152(Suppl 266):31S-S32.

Google Scholar 

Risitano AM, Araten DJ, Kuter D, et al. APPULSE-PNH: a phase IIIB trial to evaluate the efficacy and safety of switching to iptacopan in patients with paroxysmal nocturnal hemoglobinuria (PNH) on anti-C5 therapy with hemoglobin >10g/dL [abstract no. PB2063]. HemaSphere. 2023;7(Suppl 3):3967–8.

Google Scholar 

Bomback A. Design of the APPEAR-C3G study: a study to learn how well iptacopan works in people with complement 3 glomerulopathy. Future Rare Dis. 2023. https://doi.org/10.2217/frd-2022-0020.

Article  Google Scholar 

Vivarelli M, Bomback AS, Meier M, et al. Iptacopan in idiopathic immune complex–mediated membranoproliferative glomerulonephritis: protocol of the APPARENT multicenter, randomized phase 3 study. Kidney Int Rep. 2023;9(1):64–72.

Article  PubMed  PubMed Central  Google Scholar 

Kavanagh D, Greenbaum LA, Bagga A, et al. Design and rationale of the appelhus phase 3 open-label study of factor b inhibitor iptacopan for atypical hemolytic uremic syndrome. Kidney Int Rep. 2023;8(7):1332–41.

Article  PubMed  PubMed Central  Google Scholar 

Rizk DV, Rovin BH, Zhang H, et al. Targeting the alternative complement pathway with iptacopan to treat IgA nephropathy: design and rationale of the APPLAUSE-IgAN study. Kidney Int Rep. 2023;8(5):968–79.

Article  PubMed  PubMed Central  Google Scholar